AR066111A1 - Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto - Google Patents
Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuestoInfo
- Publication number
- AR066111A1 AR066111A1 ARP080101605A ARP080101605A AR066111A1 AR 066111 A1 AR066111 A1 AR 066111A1 AR P080101605 A ARP080101605 A AR P080101605A AR P080101605 A ARP080101605 A AR P080101605A AR 066111 A1 AR066111 A1 AR 066111A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cr4r8
- aromatic ring
- hydrogen
- aromatic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 101000585507 Solanum tuberosum Cytochrome b-c1 complex subunit 7 Proteins 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 101150020251 NR13 gene Proteins 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical class 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- -1 imidazole compound Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Compuesto tricíclico de imidazol de formula (1) o una sal farmacéuticamente aceptable y/o N-oxido del mismo, en el que: Z1 y Z2 se seleccionan independientemente entre CH y N; R1a y R1b se seleccionan independientemente entre hidrogeno; halogeno;ciano; alquilo C1-6; alquiltio C1-6; trifluorometilo; trifluorometoxi; carboxi; hidroxi opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6-alquilo C1-6 sustituido; alcoxi C1-6-alquilo C1-6 sustituido; hidroxialquilo C1-6; un grupo aminoopcionalmente N-sustituido con uno o dos grupos alquilo C1-6, formilo, alquil C1-6-carbonilo o alquil C1-6-sulfonilo; y aminocarbonilo en donde el grupo amino está opcionalmente sustituido con alquilo C1-4; con la condicion de que R1a y R1bsean Hcuando Z2 o Z1 es N, respectivamente; R2 es hidrogeno o alquilo C1-4, o junto con R6 forma Y segun se define a continuacion; A es un grupo de formula (2) o (3) donde: R3 es como se ha definido para R1a y R1b o es oxo y n es 1 o 2: o A es un grupo deformula (4); W1, W2 y W3 son CR4R8 o W2 y W3 son CR4R8 y W1 representa un enlace entre W3 y N, X es O, CR4R8, o NR6; un R4 es como se ha definido para R1a y R1b y el resto y R8 son hidrogeno o un R4 y R8 son juntos oxo y el resto son hidrogeno; R6es hidrogeno o alquilo C1-6; o junto con R2 forma Y; R7 es hidrogeno; halogeno; hidroxi opcionalmente sustituido con alquilo C1-6; o alquilo C1-6; Y es CR4R8CH2, CH2CR4R8, (C=O); CR4R8, CR4R8(C=O); o (C=O)CR4R8 o cuando X es CR4R8, R8 y R7representan juntos un enlace; U se selecciona entre CO y CH2 y R5 es un sistema de anillos bicíclico, carbocíclico o heterocíclico opcionalmente sustituido (5), que contiene hasta cuatro heteroátomos en cada anillo, en los que al menos uno de losanillos (a) y (b) es aromático; X1 es C o N cuando forma parte de un anillo aromático, o CR14 cuando forma parte de un anillo no aromático; X2 es N, NR13, O, S(O)x, CO o CR14 cuando es parte de un anillo aromático o no aromático, o puede ser ademásCR14R15 cuando es parte de un anillo no aromático; X3 y X5 son independientemente N o C; Y1 es un grupo enlazador de 0 a 4 átomos en el que cada átomo se selecciona independientemente entre N, NR13, O, S(O)x, CO y CR14 cuando forma parte de unanillo aromático o no aromático o puede ser adicionalmente CR14R15 cuando forma parte de un anillo no aromático; Y2 es un grupo enlazador de 2 a 6 átomos, en el que cada átomo de Y2 se selecciona independientemente entre N, NR13, O, S(O)x, CO, CR14cuando forma parte de un anillo aromático o no aromático o puede ser adicionalmente CR14R15 cuando forma parte de un anillo no aromático; cada uno de R14 y R15 se selecciona independientemente entre: H; alquiltio C1-4; halo; carboxialquilo C1-4;alquilo C1-4; alcoxi C1-4-carbonilo; alquil C1-4-carbonilo; alcoxi C1-4-alquilo C1-4; hidroxi; hidroxialquilo C1-4; alcoxi C1-4; nitro; ciano; carboxi; amina o aminocarbonilo opcionalmente mono o disustituido con alquilo C1-4; o R14 y R15 puedenrepresentar conjuntamente oxo; cada R13 es independientemente H; trifluorometilo; alquilo C1-4 opcionalmente sustituido con hidroxi, alcoxi C1-6, alquil C1-6tio, halo o trifluorometilo; alquenilo C2-4; alcoxi C1-4-carbonilo; alquil C1-4-carbonilo;alquil C1-6-sulfonilo; aminocarbonilo donde el grupo amino está opcionalmente mono o disustituido con alquilo C1-4; y cada x es independientemente 0, 1 o 2. Su uso para preparar un medicamento util para el tratamiento de infecciones bacterianas enmamíferos y composicion farmacéutica que lo comprende. Compuestos intermediarios de utilidad en la síntesis de dicho compuesto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0707705A GB0707705D0 (en) | 2007-04-20 | 2007-04-20 | Compounds |
| GB0720569A GB0720569D0 (en) | 2007-10-19 | 2007-10-19 | Compounds |
| GB0805311A GB0805311D0 (en) | 2008-03-20 | 2008-03-20 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066111A1 true AR066111A1 (es) | 2009-07-22 |
Family
ID=39580226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101605A AR066111A1 (es) | 2007-04-20 | 2008-04-18 | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8389524B2 (es) |
| EP (1) | EP2137196B1 (es) |
| JP (1) | JP5389013B2 (es) |
| KR (1) | KR101567096B1 (es) |
| CN (1) | CN101687887B (es) |
| AR (1) | AR066111A1 (es) |
| AT (1) | ATE483717T1 (es) |
| AU (1) | AU2008240764C1 (es) |
| BR (1) | BRPI0810064B8 (es) |
| CA (1) | CA2684659C (es) |
| CL (1) | CL2008001122A1 (es) |
| CO (1) | CO6251368A2 (es) |
| CR (2) | CR11123A (es) |
| CY (1) | CY1111248T1 (es) |
| DE (1) | DE602008002912D1 (es) |
| DK (1) | DK2137196T3 (es) |
| DO (1) | DOP2009000240A (es) |
| EA (1) | EA015821B1 (es) |
| HR (1) | HRP20100574T1 (es) |
| IL (1) | IL201204A0 (es) |
| MA (1) | MA31324B1 (es) |
| MX (1) | MX2009011317A (es) |
| MY (1) | MY149347A (es) |
| NZ (1) | NZ579877A (es) |
| PE (1) | PE20090274A1 (es) |
| PL (1) | PL2137196T3 (es) |
| PT (1) | PT2137196E (es) |
| SI (1) | SI2137196T1 (es) |
| TW (1) | TWI431006B (es) |
| UY (1) | UY31038A1 (es) |
| WO (1) | WO2008128942A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007081597A2 (en) * | 2005-10-21 | 2007-07-19 | Glaxo Group Limited | Peri condensed tricyclic compounds useful as antibacterial agents |
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| GB0608263D0 (en) | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
| MX2010003346A (es) * | 2007-10-19 | 2010-04-09 | Boehringer Ingelheim Int | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. |
| WO2009050236A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Neue piperazino-dihydrothienopyrimidin-derivate |
| WO2009050248A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Substituierte piperidino-dihydrothienopyrimidine |
| ES2411930T3 (es) | 2008-02-20 | 2013-07-09 | Actelion Pharmaceuticals Ltd. | Compuestos antibióticos azatricíclicos |
| ES2455496T3 (es) * | 2008-05-23 | 2014-04-15 | Glaxo Group Limited | Compuestos tricíclicos que contienen nitrógeno y su uso como agentes antibacterianos |
| WO2009141399A1 (en) * | 2008-05-23 | 2009-11-26 | Glaxo Group Limited | Tricyclic nitrogen containing compounds and their use as antibacterials |
| MY158520A (en) | 2008-10-07 | 2016-10-14 | Actelion Pharmaceuticals Ltd | Tricyclic oxazolidinone antibiotic compounds |
| JP2012505866A (ja) * | 2008-10-17 | 2012-03-08 | グラクソ グループ リミテッド | 抗菌剤として使用される三環式窒素化合物 |
| EP2387567B1 (en) | 2009-01-14 | 2014-06-11 | The Salk Institute for Biological Studies | Compounds that protect against amyloid diseases |
| AR076222A1 (es) | 2009-04-09 | 2011-05-26 | Actelion Pharmaceuticals Ltd | Derivados 2-hidroxietil-1h-quinolin-ona y sus analogos azaisotericos con actividad antibacteriana y composiciones farmaceuticas que los contienen |
| TW201130854A (en) | 2009-12-22 | 2011-09-16 | Bayer Schering Pharma Ag | Pyridinone derivatives and pharmaceutical compositions thereof |
| US8536328B2 (en) * | 2010-05-04 | 2013-09-17 | Alkermes Pharma Ireland Limited | Process for synthesizing oxidized lactam compounds |
| US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| CN103113291B (zh) * | 2013-02-04 | 2015-03-04 | 浙江大学 | 一种3位烯基吡啶衍生物的合成方法 |
| US9975910B2 (en) | 2013-07-23 | 2018-05-22 | Eisai R&D Management Co., Ltd. | Hetero-fused cyclic compound |
| AU2015304847B2 (en) * | 2014-08-22 | 2018-10-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating Neisseria gonorrhoea infection |
| EP3474846B1 (en) * | 2016-06-22 | 2022-11-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| EP3612513A4 (en) | 2017-04-17 | 2020-09-30 | Ohio State Innovation Foundation | TYPE II TOPOISOMERASE INHIBITORS AND METHOD OF MANUFACTURING AND USING THEREOF |
| JP2022528890A (ja) * | 2019-04-03 | 2022-06-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 細菌性尿路感染症の治療に使用するためのゲポチダシン |
| ES2981617T3 (es) | 2019-07-05 | 2024-10-09 | Glaxosmithkline Intellectual Property Dev | Combinación para el tratamiento de infecciones provocadas por Mycoplasma genitalium |
| JP2023528560A (ja) | 2020-04-02 | 2023-07-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ゲポチダシンを用いて淋菌感染症を治療するためのレジメン |
| EP4143188A1 (en) * | 2020-04-29 | 2023-03-08 | GlaxoSmithKline Intellectual Property Development Limited | Crystalline forms of gepotidacin |
| CN111494241B (zh) * | 2020-06-01 | 2023-03-24 | 湖北洁世达环保科技有限公司 | 一种纸巾柔润保湿液 |
| WO2022167515A1 (en) | 2021-02-05 | 2022-08-11 | Glaxosmithkline Intellectual Property Development Limited | Oral solid dose formulations |
| JP2025502442A (ja) | 2022-01-21 | 2025-01-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｓａｐｒｏｐｈｙｔｉｃｕｓによって引き起こされる感染症の処置における使用のためのゲポチダシンおよびバンコマイシン |
| EP4316463A1 (en) | 2022-08-02 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Novel formulation |
| CA3259117A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Ip Dev Ltd | GEPOTIDACIN INTENDED FOR USE IN THE TREATMENT OF BACTERIAL PROSTATITIS |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403610B1 (en) * | 1999-09-17 | 2002-06-11 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them |
| US6525049B2 (en) * | 2000-07-05 | 2003-02-25 | Pharmacia & Upjohn Company | Pyrroloquinolones as antiviral agents |
| US6624159B2 (en) * | 2000-07-12 | 2003-09-23 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| DE60125373T2 (de) * | 2000-07-26 | 2007-10-18 | Smithkline Beecham P.L.C., Brentford | Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung |
| US6603005B2 (en) * | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
| GB0031088D0 (en) * | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
| AU2002219175A1 (en) * | 2000-12-21 | 2002-07-01 | Ciba Speciality Chemicals Holding Inc. | Crystalline forms of cerivastatin sodium |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| US6602884B2 (en) | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
| GB0112834D0 (en) * | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0112836D0 (en) * | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0118238D0 (en) * | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
| WO2003048081A2 (en) * | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| AU2003239302A1 (en) * | 2002-01-29 | 2003-09-02 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| WO2003064421A1 (en) | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine derivatives |
| AR040335A1 (es) * | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto |
| AR040336A1 (es) * | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
| GB0217294D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicaments |
| FR2844270B1 (fr) * | 2002-09-11 | 2006-05-19 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent |
| FR2844268B1 (fr) * | 2002-09-11 | 2004-10-22 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent |
| WO2004035569A2 (de) * | 2002-10-10 | 2004-04-29 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue verbindungen mit antibakterieller aktivität |
| JP4704755B2 (ja) * | 2002-11-05 | 2011-06-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗菌剤 |
| JP4654035B2 (ja) * | 2002-11-05 | 2011-03-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗菌剤 |
| AR042486A1 (es) * | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
| TW200507841A (en) * | 2003-03-27 | 2005-03-01 | Glaxo Group Ltd | Antibacterial agents |
| US7232833B2 (en) * | 2003-03-28 | 2007-06-19 | Novexel | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them |
| DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| US7348434B2 (en) * | 2003-08-08 | 2008-03-25 | Antony Bigot | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them |
| FR2867472B1 (fr) | 2004-03-12 | 2008-07-18 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| US7691850B2 (en) * | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
| FR2872164B1 (fr) * | 2004-06-29 | 2006-11-17 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1773831A1 (en) | 2004-07-08 | 2007-04-18 | Glaxo Group Limited | Antibacterial agents |
| WO2006010040A2 (en) * | 2004-07-09 | 2006-01-26 | Glaxo Group Limited | Antibacterial agents |
| EP1773343A4 (en) * | 2004-07-13 | 2009-05-13 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
| JP2008507543A (ja) | 2004-07-22 | 2008-03-13 | グラクソ グループ リミテッド | 抗細菌剤 |
| ATE484509T1 (de) * | 2004-08-02 | 2010-10-15 | Glaxo Group Ltd | Antibakterielle mittel |
| US20070161627A1 (en) * | 2004-08-09 | 2007-07-12 | Miller William H | Antibacterial agents |
| DE102004041163A1 (de) * | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| JP4887297B2 (ja) | 2004-09-24 | 2012-02-29 | アクテリオン ファーマシューティカルズ リミテッド | 新規二環式抗生物質 |
| ATE466857T1 (de) * | 2004-10-05 | 2010-05-15 | Actelion Pharmaceuticals Ltd | Neue piperidin-antibiotika |
| JP5314244B2 (ja) | 2004-10-27 | 2013-10-16 | 富山化学工業株式会社 | 新規な含窒素複素環化合物およびその塩 |
| WO2006081289A2 (en) * | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| JP2008528598A (ja) * | 2005-01-25 | 2008-07-31 | グラクソ グループ リミテッド | 抗菌剤 |
| EP1845995A4 (en) * | 2005-01-25 | 2010-03-03 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
| JP2008528588A (ja) * | 2005-01-25 | 2008-07-31 | グラクソ グループ リミテッド | 抗菌剤 |
| EP1846416A4 (en) * | 2005-01-25 | 2009-07-01 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
| WO2006099884A1 (en) | 2005-03-24 | 2006-09-28 | Actelion Percurex Ag | Beta-aminoalcohol antibiotics |
| NZ562034A (en) * | 2005-03-31 | 2009-10-30 | Janssen Pharmaceutica Nv | Bicyclic pyrazole compounds as antibacterial agents |
| JP2008542249A (ja) * | 2005-05-24 | 2008-11-27 | アストラゼネカ アクチボラグ | 抗細菌活性を持つアミノピペリジンキノリン及びそのアザ等立体類似体 |
| WO2006126171A2 (en) * | 2005-05-25 | 2006-11-30 | Actelion Pharmaceuticals Ltd | New antibiotic derivatives |
| MY150958A (en) * | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| WO2006137485A1 (ja) * | 2005-06-24 | 2006-12-28 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
| WO2007081597A2 (en) * | 2005-10-21 | 2007-07-19 | Glaxo Group Limited | Peri condensed tricyclic compounds useful as antibacterial agents |
| EP1963324B1 (en) * | 2005-12-22 | 2010-04-21 | Glaxo Group Limited | Heterocyclic compounds, their preparation and their use as antibacterials |
| JP2009532423A (ja) * | 2006-04-06 | 2009-09-10 | グラクソ グループ リミテッド | 抗菌剤としてのピロロ−キノキサリノン誘導体 |
| EP2007377A4 (en) * | 2006-04-06 | 2011-08-17 | Glaxo Group Ltd | ANTIBACTERIAL ACTIVE SUBSTANCES |
| GB0608263D0 (en) * | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
| US20100256124A1 (en) * | 2006-06-09 | 2010-10-07 | David Thomas Davies | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials |
| GB0613208D0 (en) * | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| EP1992628A1 (en) * | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| GB0705672D0 (en) * | 2007-03-23 | 2007-05-02 | Glaxo Group Ltd | Compounds |
| EP1980251A1 (en) * | 2007-04-13 | 2008-10-15 | Glaxo Group Limited | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis |
| GB0707706D0 (en) * | 2007-04-20 | 2007-05-30 | Glaxo Group Ltd | Compounds |
| GB0707708D0 (en) * | 2007-04-20 | 2007-05-30 | Glaxo Group Ltd | Compounds |
| EP2005995A1 (en) * | 2007-06-22 | 2008-12-24 | Glaxo Group Limited | Heterocyclic compounds for the treatment of tuberculosis |
| GB0800367D0 (en) * | 2008-01-09 | 2008-02-20 | Glaxo Group Ltd | Compounds |
-
2008
- 2008-04-16 JP JP2010503491A patent/JP5389013B2/ja active Active
- 2008-04-16 CN CN2008800213034A patent/CN101687887B/zh active Active
- 2008-04-16 BR BRPI0810064A patent/BRPI0810064B8/pt active IP Right Grant
- 2008-04-16 PL PL08749580T patent/PL2137196T3/pl unknown
- 2008-04-16 DK DK08749580.0T patent/DK2137196T3/da active
- 2008-04-16 KR KR1020097024090A patent/KR101567096B1/ko active Active
- 2008-04-16 MX MX2009011317A patent/MX2009011317A/es active IP Right Grant
- 2008-04-16 HR HR20100574T patent/HRP20100574T1/hr unknown
- 2008-04-16 EA EA200970987A patent/EA015821B1/ru not_active IP Right Cessation
- 2008-04-16 AU AU2008240764A patent/AU2008240764C1/en active Active
- 2008-04-16 PT PT08749580T patent/PT2137196E/pt unknown
- 2008-04-16 SI SI200830103T patent/SI2137196T1/sl unknown
- 2008-04-16 WO PCT/EP2008/054621 patent/WO2008128942A1/en not_active Ceased
- 2008-04-16 MY MYPI20094376A patent/MY149347A/en unknown
- 2008-04-16 NZ NZ579877A patent/NZ579877A/en unknown
- 2008-04-16 CA CA2684659A patent/CA2684659C/en active Active
- 2008-04-16 EP EP08749580A patent/EP2137196B1/en active Active
- 2008-04-16 US US12/596,685 patent/US8389524B2/en active Active
- 2008-04-16 AT AT08749580T patent/ATE483717T1/de active
- 2008-04-16 DE DE602008002912T patent/DE602008002912D1/de active Active
- 2008-04-18 CL CL200801122A patent/CL2008001122A1/es unknown
- 2008-04-18 UY UY31038A patent/UY31038A1/es active IP Right Grant
- 2008-04-18 PE PE2008000682A patent/PE20090274A1/es active IP Right Grant
- 2008-04-18 TW TW097114042A patent/TWI431006B/zh active
- 2008-04-18 AR ARP080101605A patent/AR066111A1/es active IP Right Grant
-
2009
- 2009-09-24 IL IL201204A patent/IL201204A0/en active IP Right Grant
- 2009-10-09 DO DO2009000240A patent/DOP2009000240A/es unknown
- 2009-10-19 CO CO09116570A patent/CO6251368A2/es not_active Application Discontinuation
- 2009-10-21 MA MA32296A patent/MA31324B1/fr unknown
- 2009-11-20 CR CR11123A patent/CR11123A/es unknown
-
2010
- 2010-11-24 CY CY20101101052T patent/CY1111248T1/el unknown
-
2015
- 2015-10-23 CR CR20150586A patent/CR20150586A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
| AR061918A1 (es) | Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| AR060287A1 (es) | Compuesto de 5,6 dihidro-3h-pirrolo[1,2,3-de]quinoxalini-3-ona, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuesto intermediario util para su preparacion | |
| AR057981A1 (es) | Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR045582A1 (es) | Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1 | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| MA50065B1 (fr) | Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53 | |
| UY28578A1 (es) | Derivados de amida | |
| UY30183A1 (es) | Derivados de quinolina | |
| EA200501326A1 (ru) | Пиримидины и триазины, ингибирующие репликацию вич | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| UY28885A1 (es) | 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s) | |
| ATE360631T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| HN2010001059A (es) | Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes. | |
| UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
| AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
| ECSP056134A (es) | Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3 | |
| EA200870545A1 (ru) | Новые гетероциклические соединения | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR061015A1 (es) | Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto | |
| ECSP10010414A (es) | Compuestos tricíclicos que tienen actividad antagonista de factor de liberación de corticotropina y composiciones farmacéuticas que contienen los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |